A recent update on the President’s Emergency Plan for AIDS Relief, widely known as PEPFAR, shows a complex picture of global HIV care progress. While the number of people receiving HIV treatment remained stable through the final quarter of 2025 compared with the same period in 2024, key prevention and diagnosis metrics declined significantly.
PEPFAR, launched in 2003, has been credited with saving tens of millions of lives by expanding access to HIV treatment and prevention services across multiple countries. However, new data reported in early 2026 highlights concerns about reduced testing, fewer new diagnoses, and disruptions in preventive care services following changes and interruptions in funding and program operations.
This article explains the latest trends in HIV testing and treatment, the causes behind the decline in key indicators, and what experts are saying about the future of global HIV control efforts.
According to data released and reported in April 2026, PEPFAR supported HIV testing for approximately 17.2 million people in the final quarter of 2025. This is a sharp drop compared to 21.9 million people tested during the same period in 2024.
Alongside reduced testing, the number of new HIV diagnoses also fell. In 2025, about 307,000 new cases were identified compared to 385,000 cases the previous year. Health experts note that this decline is likely connected to reduced testing availability rather than an actual decrease in HIV transmission rates.
Fewer tests generally lead to fewer diagnoses, especially in regions where access to healthcare services is already limited or inconsistent. This raises concerns that many individuals with HIV may not be identified early enough to begin life-saving treatment.
One of the more concerning findings in the report is the drop in treatment and diagnosis among infants. Babies born with HIV require immediate medical intervention, as the disease can progress rapidly in young children without treatment.
Reports indicate that fewer infants were tested and treated during the period studied. This trend is especially troubling for global health experts because early detection in newborns is critical to reducing infant mortality linked to HIV.
Preventive care also saw major declines. The number of people receiving preventive HIV medication fell significantly, reflecting broader disruptions in healthcare delivery systems supported by PEPFAR funding.
The reported downturn in HIV testing and prevention services is linked to disruptions in program operations during 2025. According to reporting from HealthDay and The New York Times, PEPFAR activities were temporarily paused and later restarted following changes in foreign aid policy decisions.
At one point, organizations working under the program were instructed to halt distribution of HIV medications purchased with PEPFAR funds. This included supplies already stored in clinics, creating confusion and interruptions in patient care.
Although services eventually resumed, experts say the temporary pause damaged the healthcare delivery network. HIV programs rely heavily on consistent access to medication, testing kits, trained healthcare workers, and community outreach systems. Even short-term disruptions can have long-lasting effects on patient trust and service continuity.
Despite the decline in testing and prevention metrics, some officials have highlighted stable treatment numbers as a positive sign. They argue that maintaining treatment coverage demonstrates resilience in the healthcare system.
However, many global health researchers disagree with this interpretation. They emphasize that treatment alone is not enough to control the HIV epidemic. Without consistent testing and prevention programs, new infections can continue to occur unnoticed.
An economist from the Center for Global Development expressed concern that the long-term outlook could worsen if prevention services continue to decline. Advocacy groups have also warned that weakening prevention infrastructure could undermine decades of progress in HIV control.
Experts consistently stress that HIV control requires a balanced approach that includes:
High-risk groups include young women in certain regions, men who have sex with men, and individuals who use injectable drugs. These populations often face barriers to healthcare access and require specialized outreach programs.
Advocates argue that reducing investment in prevention efforts risks reversing progress made over the past two decades. When prevention services decline, new infections can rise even if treatment programs remain stable.
A key policy direction highlighted in the report is a shift toward country self-reliance in managing HIV programs. According to the U.S. State Department, approximately 3 million people are now supported through national governments rather than external aid organizations.
Supporters of this approach believe that strengthening local healthcare systems will create more sustainable long-term outcomes. However, critics caution that many countries still depend heavily on international funding and expertise to maintain HIV services at scale.
The transition to local management must be carefully supported to avoid gaps in service delivery, especially in regions with limited healthcare infrastructure.
Health advocates emphasize the need for more frequent and transparent reporting on HIV program performance. The current data reflects only a single quarter of activity, which may not fully capture long-term trends.
Experts are calling for:
Without consistent data, it becomes difficult to assess whether HIV programs are improving or declining in effectiveness.
The latest PEPFAR report presents a mixed picture of global HIV efforts. While treatment numbers have remained stable, significant declines in testing, diagnosis, and prevention services raise concerns about the long-term direction of HIV control programs.
Disruptions in 2025 appear to have affected healthcare delivery systems, highlighting the importance of stability in global health initiatives. Experts warn that continued focus on treatment alone is not enough to end the HIV epidemic.
Sustained investment in prevention, testing, and healthcare infrastructure remains essential to maintaining progress and reducing new HIV infections worldwide.
This article is for informational and educational purposes only. It is based on publicly reported data and does not constitute medical advice. Health statistics and program outcomes may change over time, and individual medical situations can vary significantly. Always consult qualified healthcare professionals for diagnosis, treatment, or medical guidance.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.